UY36152A - Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo - Google Patents

Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo

Info

Publication number
UY36152A
UY36152A UY0001036152A UY36152A UY36152A UY 36152 A UY36152 A UY 36152A UY 0001036152 A UY0001036152 A UY 0001036152A UY 36152 A UY36152 A UY 36152A UY 36152 A UY36152 A UY 36152A
Authority
UY
Uruguay
Prior art keywords
carbonitrile
triazine
oxo
phenyl
amino
Prior art date
Application number
UY0001036152A
Other languages
English (en)
Spanish (es)
Inventor
Bernat Vidal Juan
Francisco Sanchez Izquierdo
Maria Carme Serra Coma
Francesc Carrera Carrera
Juan Bautista Perez Garcia
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY36152A publication Critical patent/UY36152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001036152A 2014-05-27 2015-06-03 Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo UY36152A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382192 2014-05-27
EP14382401 2014-10-17
EP14382400 2014-10-17

Publications (1)

Publication Number Publication Date
UY36152A true UY36152A (es) 2016-01-08

Family

ID=53269467

Family Applications (3)

Application Number Title Priority Date Filing Date
UY0001036153A UY36153A (es) 2014-05-27 2015-06-03 ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?
UY0001036152A UY36152A (es) 2014-05-27 2015-06-03 Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo
UY0001036151A UY36151A (es) 2014-05-27 2015-06-03 ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001036153A UY36153A (es) 2014-05-27 2015-06-03 ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY0001036151A UY36151A (es) 2014-05-27 2015-06-03 ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.

Country Status (21)

Country Link
US (3) US20170151264A1 (zh)
EP (3) EP3148999A1 (zh)
JP (3) JP2017516799A (zh)
KR (3) KR20170007760A (zh)
CN (3) CN106414449A (zh)
AU (3) AU2015266190A1 (zh)
BR (1) BR112016024538A2 (zh)
CA (3) CA2941436A1 (zh)
CL (2) CL2016002971A1 (zh)
CR (3) CR20160536A (zh)
EA (3) EA201692437A1 (zh)
IL (3) IL247073A0 (zh)
MA (3) MA39828A (zh)
MD (3) MD20160137A2 (zh)
MX (3) MX2016014861A (zh)
PE (2) PE20170145A1 (zh)
PH (3) PH12016502255A1 (zh)
SG (3) SG11201606762PA (zh)
TW (3) TW201625260A (zh)
UY (3) UY36153A (zh)
WO (3) WO2015181055A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240452B1 (en) 2008-01-04 2019-05-29 Intellikine, LLC 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as pi3 kinase modulators, their compositions and uses
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3262046B1 (en) 2015-02-27 2020-11-04 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
RU2018140001A (ru) 2016-05-18 2020-06-18 Пикур Терапьютикс Аг Лечение повреждений кожи
GB201608797D0 (en) * 2016-05-19 2016-07-06 Ucb Biopharma Sprl Therapeutic use
CN107456454A (zh) * 2016-06-06 2017-12-12 先声药业有限公司 一种预防或治疗炎性疾病的药物组合物
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
CN110520097B (zh) 2017-01-06 2023-10-27 帕尔维拉治疗股份有限公司 Mtor抑制剂的无水组合物及其使用方法
GB201708856D0 (en) * 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms
WO2019101853A1 (en) * 2017-11-23 2019-05-31 Piqur Therapeutics Ag Treatment of skin disorders
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
CN113440614A (zh) * 2020-03-26 2021-09-28 长沙晶易医药科技有限公司 一种用于治疗类风湿性关节炎的组合物及其应用
KR20230065591A (ko) * 2021-11-05 2023-05-12 연세대학교 산학협력단 피부-특이적 T 세포(skin-specific T cell)의 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
US20230190755A1 (en) * 2021-12-16 2023-06-22 Incyte Corporation Topical formulations of PI3K-delta inhibitors
TWI823476B (zh) * 2022-07-15 2023-11-21 中化合成生技股份有限公司 托法替尼檸檬酸鹽的製備方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569406A1 (en) * 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
AU2006283846B2 (en) * 2005-08-26 2012-04-05 Merck Serono Sa Pyrazine derivatives and use as PI3K inhibitors
EA019499B1 (ru) * 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors

Also Published As

Publication number Publication date
CA2944611A1 (en) 2015-12-03
JP2017516798A (ja) 2017-06-22
CA2941436A1 (en) 2015-12-03
TW201625259A (zh) 2016-07-16
MX2016014864A (es) 2017-04-06
SG11201606762PA (en) 2016-09-29
MX2016014861A (es) 2017-04-06
JP2017516799A (ja) 2017-06-22
TW201625258A (zh) 2016-07-16
MD20160138A2 (ro) 2017-05-31
SG11201607950SA (en) 2016-10-28
EP3148999A1 (en) 2017-04-05
KR20170012236A (ko) 2017-02-02
MD20160132A2 (ro) 2017-05-31
KR20170010369A (ko) 2017-01-31
US20170151264A1 (en) 2017-06-01
IL247072A0 (en) 2016-09-29
EP3148585A1 (en) 2017-04-05
AU2015266190A1 (en) 2016-10-20
MX2016014904A (es) 2017-02-28
US20170189409A1 (en) 2017-07-06
MA39827A (fr) 2015-12-03
CN107074862A (zh) 2017-08-18
UY36151A (es) 2016-01-08
CN106414449A (zh) 2017-02-15
US20170158699A1 (en) 2017-06-08
EA201692436A1 (ru) 2017-04-28
WO2015181053A1 (en) 2015-12-03
MD20160137A2 (ro) 2017-05-31
WO2015181055A1 (en) 2015-12-03
MA39829A (fr) 2015-12-03
EA201692435A1 (ru) 2017-04-28
IL247901A0 (en) 2016-11-30
CR20160536A (es) 2017-01-02
KR20170007760A (ko) 2017-01-20
MA39828A (fr) 2015-12-03
CL2016002971A1 (es) 2017-02-17
SG11201606763VA (en) 2016-09-29
AU2015266191A1 (en) 2016-09-15
CN106456777A (zh) 2017-02-22
PE20170145A1 (es) 2017-03-10
CL2016002970A1 (es) 2017-02-10
AU2015266193A1 (en) 2016-09-15
PH12016502255A1 (en) 2017-02-06
IL247073A0 (en) 2016-09-29
EP3148586A1 (en) 2017-04-05
TW201625260A (zh) 2016-07-16
CA2941429A1 (en) 2015-12-03
JP2017516797A (ja) 2017-06-22
EA201692437A1 (ru) 2017-04-28
PH12016502252A1 (en) 2017-02-06
WO2015181052A1 (en) 2015-12-03
PE20170385A1 (es) 2017-04-09
PH12016502256A1 (en) 2017-02-06
UY36153A (es) 2016-01-08
CR20160538A (es) 2017-01-02
CR20160537A (es) 2017-03-17
BR112016024538A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
UY36152A (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
GT201400196A (es) Compuestos de heterociclilo
CR20150524A (es) Compuestos de heteroarilo y sus usos
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
UY34540A (es) Heteroarilos y usos de los mismos
DOP2019000290A (es) Inhibidores de quinasa y usos de los mismos
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY34018A (es) Derivados glucósidos y usos de los mismos
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
CO2019008110A2 (es) Activador de nrf2
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
AR100620A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230508